title: Effects of rosiglitazone treatment on insulin resistance and TNF-alpha levels in patients with chronic kidney disease: a prospective study.
abstract: OBJECTIVE
  The aim of the study was to investigate the effects of rosiglitazone treatment on insulin resistance (IR) and tumor necrosis factor-alpha (TNF-alpha) levels in non-diabetic chronic kidney disease (CKD) patients with IR.
  
  
  METHODS
  Thirty non-diabetic CKD patients with IR were enrolled in the study. Patients were grouped into two: group 1 (n = 15) received rosiglitazone 4 mg tablet for 3 months and patients who did not receive rosiglitazone treatment constituted the group 2 (n = 15). Baseline and after rosiglitazone treatment, homeostatis model assessment-insulin resistance (HOMA-IR) and TNF-alpha levels were measured.
  
  
  RESULTS
  There were no statistical differences in gender, age, HOMA-IR and TNF-alpha levels among group 1 and group 2 (p > 0.05 for all). Compared to baseline in group 1, significant differences were found in HOMA-IR and TNF-alpha levels after 3 months (p = 0.023; p = 0.001, respectively).
  
  
  CONCLUSIONS
  Our study indicates that, rosiglitazone treatment improves the IR and decreases TNF-alpha levels in non-diabetic patients CKD with IR.
authors.affiliation: Department of Nephrology, Sisli Etfal Education and Research Hospital, Istanbul, Turkey. tanerbast@yahoo.com
authors.forename: T
authors.initials: T
authors.lastname: Basturk
authors.forename: A
authors.initials: A
authors.lastname: Unsal
authors.forename: T
authors.initials: T
authors.lastname: Ulas
authors.forename: Y
authors.initials: Y
authors.lastname: Koc
authors.forename: T
authors.initials: T
authors.lastname: Sakaci
authors.forename: E
authors.initials: E
authors.lastname: Ahbap
authors.forename: F
authors.initials: F
authors.lastname: Borlu
mesh_terms: D001786:Blood Glucose / Q000032:analysis; D001794:Blood Pressure / Q000187:drug effects; D002097:C-Reactive Protein / Q000032:analysis; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D007333:Insulin Resistance; D011446:Prospective Studies; D051436:Renal Insufficiency, Chronic / Q000097:blood* / Q000503:physiopathology; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000494:pharmacology*; D014409:Tumor Necrosis Factor-alpha / Q000097:blood*
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D014409:Tumor Necrosis Factor-alpha; D000077154:Rosiglitazone; D002097:C-Reactive Protein